Medical and surgical interventions for neurotrophic keratopathy

Kruoch Z, Choo AY, Kemp A, Gonzales M, Yim TW, McCann P, Liu SH, Ting DSJ, Kuo IC · Cochrane Database of Systematic Reviews

The independent appraisal of the Tβ4 keratopathy trial: risk ratio 9.00 for corneal re-epithelialisation, 95% CI 0.57 to 141.88, 18 participants, low-certainty evidence — a confidence interval spanning no effect. Recombinant human nerve growth factor was the only intervention with pooled evidence of benefit.

Population

Seven randomised trials of medical or surgical treatment for neurotrophic keratopathy

Intervention

Various, including 0.1% RGN-259 (Tβ4)

Comparator

Vehicle, artificial tears or alternative treatment

Limitations

Reviews an already small trial; five of the seven included studies that reported funding were industry-sponsored.